Xenon Pharmaceuticals (XENE) reported a Q4 net loss late Tuesday of $0.84 per diluted share, widening from a loss of $0.64 a year earlier.
Analysts polled by FactSet expected a loss of $0.88.
No revenue was recorded in the three months ended Dec. 31, as expected.
The company had $754.4 million in cash, cash equivalents and marketable securities at the end of December and expects to have sufficient liquidity to fund operations into 2027.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。